Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2021 to Q3 2025

Type / Class
Equity / Common Stock
Symbol
ANEB on Nasdaq
Shares outstanding
41,061,008
Price per share
$0.99
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
22,219,763
Total reported value
$55,549,711
% of total 13F portfolios
0%
Share change
-372,183
Value change
-$356,433
Number of holders
20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
English Aron R. 51% 0% $25,877,258 21,929,880 0% Aron R. English 24 Feb 2025
Nantahala Capital Management, LLC 8.6% $4,185,930 3,547,398 Nantahala Capital Management, LLC 31 Dec 2024
MANGROVE PARTNERS IM, LLC 6.2% $2,979,797 2,525,252 Mangrove Partners IM, LLC 31 Dec 2024

As of 30 Sep 2025, 20 institutional investors reported holding 22,219,763 shares of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB). This represents 54% of the company’s total 41,061,008 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
22NW, LP 38% 15,467,300 0% 20% $38,668,250
Nantahala Capital Management, LLC 7.4% 3,036,325 0% 0.47% $7,590,812
MANGROVE PARTNERS IM, LLC 6.2% 2,525,252 0% 0.47% $6,313,130
MORGAN STANLEY 0.97% 399,404 +0.05% 0% $998,511
VANGUARD GROUP INC 0.75% 306,540 +42% 0% $766,351
GEODE CAPITAL MANAGEMENT, LLC 0.42% 174,108 -15% 0% $435,570
Ikarian Capital, LLC 0.38% 157,720 0% 0.09% $394,300
RENAISSANCE TECHNOLOGIES LLC 0.07% 28,500 0% $71,250
NORTHERN TRUST CORP 0.06% 24,393 0% $60,983
BlackRock, Inc. 0.06% 24,060 +40% 0% $60,150
Rangeley Capital, LLC 0.05% 20,000 0.05% $50,000
XTX Topco Ltd 0.05% 19,153 0% $47,883
BOOTHBAY FUND MANAGEMENT, LLC 0.05% 18,836 0% 0% $47,090
STATE STREET CORP 0.03% 12,768 0% $31,920
JPMORGAN CHASE & CO 0.01% 2,138 0% $5,345
Tower Research Capital LLC (TRC) 0% 1,750 -46% 0% $4,375
BANK OF AMERICA CORP /DE/ 0% 891 -74% 0% $2,228
BARCLAYS PLC 0% 399 0% $998
UBS Group AG 0% 220 +139% 0% $550
CITIGROUP INC 0% 6 0% $15
GOLDMAN SACHS GROUP INC 0% 0 -100% $0
Ameritas Advisory Services, LLC 0% 0 -100% $0
PNC Financial Services Group, Inc. 0% 0 -100% $0
LVW Advisors, LLC 0% 0 -100% $0
MILLENNIUM MANAGEMENT LLC 0% 0 -100% $0

Institutional Holders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 22,219,763 $55,549,711 -$356,433 $2.50 20
2025 Q2 22,591,946 $32,532,431 -$34,513 $1.44 18
2025 Q1 22,618,242 $29,403,638 +$39,506 $1.30 18
2024 Q4 22,570,347 $37,311,560 +$24,974,043 $1.68 15
2024 Q3 7,343,734 $14,173,448 +$69,135 $1.93 13
2024 Q2 7,307,778 $19,950,292 +$326 $2.73 12
2024 Q1 7,306,365 $20,969,328 +$85,916 $2.87 14
2023 Q4 7,278,993 $17,615,165 +$183,945 $2.42 13
2023 Q3 7,050,491 $21,560,562 +$51,779 $3.06 11
2023 Q2 7,031,883 $16,498,373 +$460,020 $2.35 11
2023 Q1 6,836,130 $19,834,339 -$508,787 $2.90 9
2022 Q4 7,046,307 $17,074,708 -$15,992 $2.42 12
2022 Q3 6,842,912 $19,161,000 +$6,062,684 $2.80 10
2022 Q2 4,677,847 $24,324,000 +$2,192,344 $5.20 8
2022 Q1 4,190,412 $29,539,000 -$21,602 $7.02 8
2021 Q4 4,193,307 $25,818,000 +$61,833 $6.21 8
2021 Q3 4,183,214 $27,472,000 -$109,295 $6.58 7
2021 Q2 4,199,813 $28,670,000 +$28,670,000 $6.85 8